The Korean medication algorithm for depressive disorder: Second revision

Journal of Affective Disorders

Volumn 167, Issue , 2014, Pages 312-321

  Seok Seo, Jeong ^a   Rim Song, Hoo ^b   Bin Lee, Hwang ^c   Park, Young Min ^d   Hong, Jeong Wan ^e   Kim, Won ^f   Wang, Hee Ryung ^b   Lim, Eun Sung ^g   Jeong, Jong Hyun ^h   Jon, Duk In ⁱ   Joon Min, Kyung ^j   Sup Woo, Young ^b   Bahk, Won Myong ^b  

^a Konkuk University School of Medicine   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c Seoul National University Hospital   (South Korea)

^d Inje University   (South Korea)

^e Department of Psychiatry Namwon Sungil Mental Hospital   (South Korea)

^f Inje University College of Medicine   (South Korea)

^g Department of Diagnostic Radiology   (South Korea)

^h The Catholic University of Korea   (South Korea)

ⁱ Hallym University   (South Korea)

^j Chung Ang University   (South Korea)

more..

Author keywords

Algorithm; Depressive disorder; Guideline; Revision

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; MILNACIPRAN; MIRTAZAPINE; OLANZAPINE; PAROXETINE; QUETIAPINE; SERTRALINE; VENLAFAXINE; NEUROLEPTIC AGENT;

ARTICLE; BIOLOGICAL THERAPY; CONSENSUS; DEPRESSIVE PSYCHOSIS; DRUG SAFETY; DYSTHYMIA; GROUPS BY AGE; HUMAN; KOREAN MEDICATION ALGORITHM FOR DEPRESSIVE DISORDER; MAINTENANCE THERAPY; MAJOR DEPRESSION; MONOTHERAPY; PHARMACEUTICAL CARE; PRACTICE GUIDELINE; PREMENSTRUAL DYSPHORIC DISORDER; PRIORITY JOURNAL; PSYCHIATRIC TREATMENT; PSYCHOSIS; PUERPERAL DEPRESSION; QUESTIONNAIRE; SEASONAL AFFECTIVE DISORDER; TREATMENT DURATION; ADOLESCENT; ADULT; AGED; ALGORITHM; BIPOLAR DISORDER; CHILD; COMORBIDITY; CONSENSUS DEVELOPMENT; DEPRESSION, POSTPARTUM; DEPRESSIVE DISORDER; DEPRESSIVE DISORDER, MAJOR; DRUG COMBINATION; DYSTHYMIC DISORDER; FEMALE; MALE; MIDDLE AGED; PSYCHOLOGY; SOUTH KOREA; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ALGORITHMS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CHILD; COMORBIDITY; DEPRESSION, POSTPARTUM; DEPRESSIVE DISORDER; DEPRESSIVE DISORDER, MAJOR; DRUG THERAPY, COMBINATION; DYSTHYMIC DISORDER; FEMALE; HUMANS; MALE; MIDDLE AGED; PREMENSTRUAL DYSPHORIC DISORDER; REPUBLIC OF KOREA; YOUNG ADULT;

EID: 84904012981     PISSN: 01650327     EISSN: 15732517     Source Type: Journal    
DOI: 10.1016/j.jad.2014.05.031     Document Type: Article

References (57)

1. APA Practice Guideline for the Treatment of Patients with Major Depressive Disorder second ed. 2000 American Psychiatric Association Arlington, VA
2. APA Practice guideline for the treatment of patients with major depressive disorder third ed. 2010 American psychiatric association Arlington, VA
3. Alexopoulos, G.S., Katz, I.R., Reynolds, C.F., 2001, 3rd, Carpenter, D., Docherty, J. P. & Expert consensus panel for pharmacotherapy of depressive disorders in older, P. The expert consensus guideline series. Pharmacotherapy of depressive disorders in older patients. Postgrad Med, Spec No Pharmacotherapy, pp. 1-86.
4. L.L. Altshuler, L.S. Cohen, M.L. Moline, D.A. Kahn, D. Carpenter, J.P. Docherty, and W. Expert Consensus Panel For Depression In The expert consensus guideline series. Treatment of depression in women Postgrad. Med. 2001 1 107
5. R.J. Anderson, K.E. Freedland, R.E. Clouse, and P.J. Lustman The prevalence of comorbid depression in adults with diabetes: a meta-analysis Diabetes Care 24 2001 1069 1078
6. M. Bauer, T. Bschor, A. Pfennig, P.C. Whybrow, J. Angst, M. Versiani, H.J. Moller, and W.T.F.O.U.D. Disorders World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders in primary care World J. Biol. Psychiatry 8 2007 67 104
7. M. Bauer, H.W. Pretorius, E.L. Constant, W.R. Earley, J. Szamosi, and M. Brecher Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study J. Clin Psychiatry 70 2009 540 549
8. M.S. Bauer, S.R. Wisniewski, L.B. Marangell, C.A. Chessick, M.H. Allen, E.B. Dennehy, D.J. Miklowitz, M.E. Thase, and G.S. Sachs Are antidepressants associated with new-onset suicidality in bipolar disorder? A prospective study of participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) J. Clin. Psychiatry 67 2006 48 55
9. R.M. Berman, R.N. Marcus, R. Swanink, R.D. Mcquade, W.H. Carson, P.K. Corey-Lisle, and A. KHAN The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study J. Clin. Psychiatry 68 2007 843 853
10. B. Birmaher, D. Brent, A.W.G.O.Q. Issues, W. Bernet, O. Bukstein, H. Walter, R.S. Benson, A. Chrisman, T. Farchione, L. Greenhill, J. Hamilton, H. Keable, J. Kinlan, U. Schoettle, S. Stock, K.K. Ptakowski, and J. Medicus Practice parameter for the assessment and treatment of children and adolescents with depressive disorders J. Am. Acad. Child Adolesc. Psychiatry 46 2007 1503 1526
11. B. Bortnick, N. El-Khalili, M. Banov, D. Adson, C. Datto, S. Raines, W. Earley, and H. Eriksson Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: a placebo-controlled, randomized study J. Affect. Disord. 128 2011 83 94
12. D.D. Buff, R. Brenner, S.S. Kirtane, and R. Gilboa Dysrhythmia associated with fluoxetine treatment in an elderly patient with cardiac disease J. Clin. Psychiatry 52 1991 174 176
13. A.H. Cheung, R.A. Zuckerbrot, P.S. Jensen, K. Ghalib, D. Laraque, R.E. Stein, and G.-P.S. Group Guidelines for Adolescent Depression in Primary Care (GLAD-PC): II. Treatment and ongoing management Pediatrics 120 2007 e1313 e1326
14. A.H. Clayton, J.F. Pradko, h.A. Croft, C.B. Montano, R.A. Leadbetter, C. Bolden-Watson, K.I. Bass, R.M. Donahue, B.D. Jamerson, and A. Metz Prevalence of sexual dysfunction among newer antidepressants J. Clin. Psychiatry 63 2002 357 366
15. K.R. Connolly, and M.E. Thase If at first you don't succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies Drugs 71 2011 43 64
16. G.E. Crane The psychiatric side-effects of iproniazid Am. J. Psychiatry 112 1956 494 501
17. H. Croft, T.L. Houser, B.D. Jamerson, R. Leadbetter, C. Bolden-Watson, R. Donahue, and A. Metz Effect on body weight of bupropion sustained-release in patients with major depression treated for 52 weeks Clin. Ther. 24 2002 662 672
18. A.J. Cutler, S.A. Montgomery, D. Feifel, A. Lazarus, M. Astrom, and M. Brecher Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study J. Clin. Psychiatry 70 2009 526 539
19. E.H. Friedman Fluoxetine-induced bradycardia J. Clin. Psychiatry 52 1991 477
20. R.W. Fuller, K.W. Perry, and B.B. Molloy Effect of an uptake inhibitor on serotonin metabolism in rat brain: studies with 3-(p-trifluoromethylphenoxy)-N- methyl-3-phenylpropylamine (Lilly 110140) Life Sci. 15 1974 1161 1171
21. S. Gerson, T.R. Belin, A. Kaufman, J. Mintz, and L. Jarvik Pharmacological and psychological treatments for depressed older patients: a meta-analysis and overview of recent findings Harv. Rev. Psychiatry 7 1999 1 28
22. P. Ghaeli, E. Shahsavand, M. Mesbahi, M.Z. Kamkar, M. Sadeghi, and S. Dashti-Khavidaki Comparing the effects of 8-week treatment with fluoxetine and imipramine on fasting blood glucose of patients with major depressive disorder J. Clin. Psychopharmacol. 24 2004 386 388
23. S.N. Ghaemi, J.Y. Ko, and F.K. Goodwin Cade's disease" and beyond: misdiagnosis, antidepressant use, and a proposed definition for bipolar spectrum disorder Can. J. Psychiatry 47 2002 125 134
24. D. Gill, and S. Hatcher A systematic review of the treatment of depression with antidepressant drugs in patients who also have a physical illness J. Psychosom. Res. 47 1999 131 143
25. R.A. Hansen, G. Gartlehner, K.N. Lohr, B.N. Gaynes, and T.S. Carey Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder Ann. Intern. Med. 143 2005 415 426
26. C.W. Hughes, G.J. Emslie, M.L. Crismon, K. Posner, B. Birmaher, N. Ryan, P. Jensen, J. Curry, B. Vitiello, M. Lopez, S.P. Shon, S.R. Pliszka, M.H. Trivedi, and D. Texas Consensus Conference Panel On Medication Treatment Of Childhood Major Depressive Texas children's medication algorithm project: update from texas consensus conference panel on medication treatment of childhood major depressive disorder J. Am Acad. Child Adolesc. Psychiatry 46 2007 667 686
27. H. Katila, I. Mezhebovsky, A. Mulroy, L. Berggren, H. Eriksson, W. Earley, and C. Datto Randomized, double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (Quetiapine XR) monotherapy in elderly patients with major depressive disorder Am. J. Geriatr. Psychiatry 21 2013 769 784
28. W. Katon, M. Von Korff, E. Lin, T. BUSH, and J. Ormel Adequacy and duration of antidepressant treatment in primary care Med. Care 30 1992 67 76
29. R.W. Lam, S.H. Kennedy, S. Grigoriadis, R.S. Mcintyre, R. Milev, R. Ramasubbu, S.V. PARIKH, S.B. Patten, A.V. Ravindran, M. Canadian Network For, and T. Anxiety Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy J. Affect. Disord. 117 Suppl 1 2009 S26 S43
30. M.S. Lee, S.W. Lim, J.H. Cha, S.K. Chung, and K.S. Kim The executive committee for the korean medication algorithm projects for major depressive disorder. The Korean Medication Algorithm for Major Depressive Disorder (KMA-MDD): report of the korean society of depressive and bipolar disorders Int. J. Psychiatry Clin. Pract. 10 2006 186 194
31. M.P. Luber, J.P. Hollenberg, P. Williams-Russo, T.N. Didomenico, B.S. Meyers, G.S. Alexopoulos, and M.E. Charlson Diagnosis, treatment, comorbidity, and resource utilization of depressed patients in a general medical practice Int. J. Psychiatry Med. 30 2000 1 13
32. M.P. Luber, B.S. Meyers, P.G. Williams-Russo, J.P. Hollenberg, T.N. Didomenico, M.E. Charlson, and G.S. Alexopoulos Depression and service utilization in elderly primary care patients Am. J. Geriatr. Psychiatry 9 2001 169 176
33. J.G. Modell, N.E. Rosenthal, A.E. Harriett, A. Krishen, A. Asgharian, V.J. Foster, A. Metz, C.B. Rockett, and D.S. Wightman Seasonal affective disorder and its prevention by anticipatory treatment with bupropion XL Biol. Psychiatry 58 2005 658 667
34. J.C. Nelson, and G.I. Papakostas Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials Am. J. Psychiatry 166 2009 980 991
35. R.C. Ng, C.K. Hirata, W. Yeung, E. Haller, and P.R. Finley Pharmacologic treatment for postpartum depression: a systematic review Pharmacotherapy 30 2010 928 941
36. Nice Quick Reference Guide, Depression: Management of Depression in Primary and Secondary Care 2004 The National Institute for Clinical Excellence (NICE) London
37. M.M. Ohayon, and A.F. Schatzberg Using chronic pain to predict depressive morbidity in the general population Arch. Gen. Psychiatry 60 2003 39 47
38. P. Pacher, Z. Ungvari, P.P. Nanasi, S. Furst, and V. Kecskemeti Speculations on difference between tricyclic and selective serotonin reuptake inhibitor antidepressants on their cardiac effects. Is there any? Curr. Med. Chem. 6 1999 469 480
39. G.I. Papakostas, and M. Fava A metaanalysis of clinical trials comparing moclobemide with selective serotonin reuptake inhibitors for the treatment of major depressive disorder Can. J. Psychiatry 51 2006 783 790
40. D.G. Perahia, Y.L. Pritchett, D.K. Kajdasz, M. Bauer, R. JAIN, J.M. Russell, D.J. Walker, K.A. SPENCER, D.M. Froud, J. Raskin, and M.E. Thase A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder J. Psychiatr. Res. 42 2008 22 34
41. S. Pilling, I. Anderson, D. Goldberg, N. Meader, C. Taylor, and G. Two guideline development Depression in adults, including those with a chronic physical health problem: summary of NICE guidance BMJ 339 2009 b4108
42. C.L. Raison, and A.H. Miller When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders Am. J. Psychiatry 160 2003 1554 1565
43. B. Rudisch, and C.B. Nemeroff Epidemiology of comorbid coronary artery disease and depression Biol. Psychiatry 54 2003 227 240
44. A.J. Rush, M. Fava, S.R. Wisniewski, P.W. LAVORI, M.H. Trivedi, H.A. Sackeim, M.E. Thase, A.A. Nierenberg, F.M. Quitkin, T.M. Kashner, D.J. Kupfer, J.F. Rosenbaum, J. Alpert, J.W. Stewart, P.J. Mcgrath, M.M. BIGGS, K. Shores-Wilson, B.D. Lebowitz, L. Ritz, G. Niederehe, and S.D.I. Group Sequenced treatment alternatives to relieve depression (STAR-D): rationale and design Control.Clin. Trials 25 2004 119 142
45. Sachs, G.S., Printz, D.J., Kahn, D.A., Carpenter, D., Docherty, J.P. 2000. The expert consensus guideline series: medication treatment of bipolar disorder 2000. Postgrad. Med., Spec. No., 1-104.
46. J.J. Schildkraut The catecholamine hypothesis of affective disorders: a review of supporting evidence Am J. Psychiatry 122 1965 509 522
47. J.S. Seo, K.J. Min, W. Kim, J.H. Seok, W.M. Bahk, and H.C. Song Korean medication algorithm for depressive disorder 2006 (I) J. Korean Neuropsychiatr. Assoc. 46 2007 453 460
48. J.A. Sirey, M.L. Bruce, G.S. Alexopoulos, D.A. Perlick, S.J. Friedman, and B.S. Meyers Stigma as a barrier to recovery: perceived stigma and patient-rated severity of illness as predictors of antidepressant drug adherence Psychiatr. Serv. 52 2001 1615 1620
49. W.D. Taylor, and P.M. Doraiswamy A systematic review of antidepressant placebo-controlled trials for geriatric depression: limitations of current data and directions for the future Neuropsychopharmacology 29 2004 2285 2299
50. L. Thorpe, D.K. Whitney, S.P. Kutcher, S.H. Kennedy, and C.D.W. Group Clinical guidelines for the treatment of depressive disorders. VI. Special populations Can. J. Psychiatry 46 Suppl 1 2001 63S 76S
51. M.H. Trivedi, S.S. Henley, M.L. Crismon, and T. Key Texas Implementation of Medication Algorithms (TIMA) Guidelines for Treating Major Depressive Disorder, revised. 2000 1 91
52. US FDA drug safety communication: revised recommendations for Celexa (citalopram hydrobromide) 2012related to a potential risk of abnormal heart rhythms with high doses [Online]. 〈http://www.fda.gov/Drugs/DrugSafety/ ucm297391.htm〉
53. US FDA 2004 Suicidality in children and adolescents being treated with antidepressant medications. US Food and Drug Association. [Online]. 〈http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm161679. htm〉.
54. US Food 2007 and Drug Administration Public Health Advisory [Online]. 〈http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm096273. htm〉.
55. N. Watanabe, I.M. Omori, A. Nakagawa, A. Cipriani, C. Barbui, R. Churchill, and T.A. Furukawa Mirtazapine versus other antidepressive agents for depression Cochrane Database Syst. Rev. 2011 CD006528, 10.1002/14651858
56. E.M. Whyte, and B.H. Mulsant Post stroke depression: epidemiology, pathophysiology, and biological treatment Biol. Psychiatry 52 2002 253 264
57. R.A. Zuckerbrot, A.H. Cheung, P.S. Jensen, R.E. Stein, D. Laraque, and G.-P.S. Group Guidelines for Adolescent Depression in Primary Care (GLAD-PC): I. Identification, assessment, and initial management Pediatrics 120 2007 e1299 e1312